John
Hulleman

John Hulleman, PhD, is originally from Wausau, Wisconsin. He received dual undergraduate degrees in biology and chemistry at the University of St. Thomas in St. Paul, Minnesota, and graduated cum laude. He earned a PhD in Medicinal Chemistry and Molecular Pharmacology at Purdue University. There, under the guidance of Dr. Jean-Christophe Rochet, he studied how misfolded proteins cause early-onset Parkinson’s disease. Subsequently, he did postdoctoral research in the laboratory of Dr. Jeffery Kelly at The Scripps Research Institute, where he focused on how an R345W mutation in fibulin-3 causes a rare, early-onset form of macular degeneration.

In 2014, Dr. Hulleman joined UT Southwestern’s Department of Ophthalmology. His research focuses on novel therapeutic approaches for eye diseases, including AMD and other retinal degenerative diseases. Dr. Hulleman has a secondary appointment in the Department of Pharmacology and is affiliated with the Biological Chemistry Graduate Program at UT Southwestern.